Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial.

A Food and Drug Administration (FDA) safety communication in August 2011 warned that citalopram was associated with a dose dependent risk of QT prolongation and recommended dose restriction in patients over the age of 60 but did not provide data for this age group.CitAD was a randomized, double-mask...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lea T Drye, David Spragg, D P Devanand, Constantine Frangakis, Christopher Marano, Curtis L Meinert, Jacobo E Mintzer, Cynthia A Munro, Gregory Pelton, Bruce G Pollock, Anton P Porsteinsson, Peter V Rabins, Paul B Rosenberg, Lon S Schneider, David M Shade, Daniel Weintraub, Jerome Yesavage, Constantine G Lyketsos, CitAD Research Group
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science (PLoS) 2014-01-01
Colecção:PLoS ONE
Acesso em linha:http://europepmc.org/articles/PMC4051660?pdf=render
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados